• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 35
  • 28
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 2
  • 1
  • Tagged with
  • 87
  • 87
  • 87
  • 29
  • 28
  • 28
  • 25
  • 19
  • 15
  • 14
  • 13
  • 12
  • 11
  • 10
  • 10
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
61

"Emissões otoacústicas produto de distorção em recém-nascidos medicados com ototóxicos" / Distortion product otoacoustic emission in newborn exposed to ototoxic

Marone, Marisa Ruggieri 22 June 2006 (has links)
INTRODUÇÃO: Os aminoglicosídeos são freqüentemente usados no berçário e podem ser tóxicos para as células ciliadas cócleo-vestibulares, especialmente para as células ciliadas externas da base da cóclea. As emissões ototacústicas produto de distorção permitem avaliar porções específicas da cóclea, antes mesmo que a sensação auditiva seja alterada, sendo ideais para análise precoce da integridade dessa estrutura auditiva, além de ser indicada para recém-nascidos por serem objetivas. O objetivo deste estudo prospectivo longitudinal é pesquisar a amplitude das emissões otoacústicas produto de distorção, causadas pelo uso de drogas ototóxicas, entre o término da administração e de 15 a 40 dias após seu uso. MÉTODOS: A população foi de recém-nascidos a termo e pré-termo provenientes de berçário e maternidade de um hospital público em Santo André, no período de julho de 2003 a setembro de 2004. A primeira avaliação ocorreu no dia da alta hospitalar. Foram avaliados três grupos: grupo controle com 33 recém-nascidos saudáveis e de termo; grupo de estudo a termo exposto a amicacina e /ou vancomicina com 19 recém-nascidos com mais de 37 semanas e grupo de estudo pré-termo exposto aos mesmos ototóxicos, com 15 recém-nascidos de 32 a 37 semanas. Os recém-nascidos não apresentavam indicadores de risco para deficiência auditiva preconizados pelo JCIH,2000 concomitante à infecção neonatal. Todos os recém-nascidos foram avaliados com idade gestacional corrigida maior que 37 semanas. As amplitudes das emissões otoacústicas dos recém-nascidos em fase de alta hospitalar foram comparadas às obtidas de 15 a 40 dias após a alta. RESULTADOS: As amplitudes das emissões otoacústicas dos recém-nascidos do grupo de estudo pré-termo foram menores que as amplitudes do grupo controle e do grupo de estudo a termo nos dois momentos de teste. As amplitudes das emissões dos recém-nascidos dos três grupos aumentaram no segundo momento de teste. As amplitudes das emissões dos recém-nascidos foram maiores na freqüência de 6.000 Hz e na orelha direita para a freqüência f2 3.000 Hz. As amplitude das emissões do grupo controle no segundo momento de teste foram semelhantes as do grupo de estudo à termo no primeiro momento da pesquisa. CONCLUSÔES: Houve aumento da amplitude das emissões otoacústicas produto de distorção desde a fase de alta até 15 a 40 dias após. A exposição a amicacina e vancomicina nas doses preconizadas pelo Neofax®, 2003/2004 não alterou as amplitudes das emissões nos recém-nascidos sem indicadores de risco concomitante à infecção neonatal. / The amynoglicosides are frequently used in nurseries and may be toxic for the cochleo-vestibular hair cells, specially for the outer cells of the cochlear base. The distortion product otoacoustic emissions allow to evaluate specific portions of the cochlea even before the hearing sensation is altered, and are ideal for the early analysis of this auditory structure integrity, besides being indicated for newborns once they are objective. The aim of this prospective longitudinal study is to research the amplitude of distortion product otoacoustic emissions caused by the ototoxic drugs use, between the end of the administration and from 15 to 40 days after its use. The population studied was composed by term and preterm newborns from a nursery and maternity of a Santo André city hospital, in the period from July 2003 to September 2004. The first evaluation occurred on the hospital discharge day. Three groups were evaluated: control group with 33 term and healthy newborns; term study group with 19 term newborns with more than 37 weeks exposed to amicacin and/or vancomycin; and preterm study group with 15 preterm newborns from 32 to 37 weeks exposed to the same ototoxic. The newborns did not present risk factors for hearing loss according to the JCIH, 2000 concomitant to the neonatal infection. All newborns were evaluated at a corrected gestational age greater than 37 weeks. The otoacoustic emissions amplitudes obtained at the hospital discharge were compared to the ones obtained from 15 to 40 days after the discharge. The results showed that the otoacoustic emissions amplitudes of the preterm study group were smaller than the amplitudes of the control group and the term study group in both moments of the test. The amplitude of the newborns’ otoacoustic emissions increased in the second moment of the test. The amplitudes were higher in the frequency of 6.000Hz and, in the right ear in the frequency f2 3.000 Hz. The otoacoustic emissions amplitudes of the control group in the second moment of the test were similar to the term study group in the first moment of the research. It was concluded that there is an increase of the distortion product otoacoustic emissions amplitude from the discharge moment until 15 to 40 days after, suggesting a maturation of the cochlear structures in the post-natal period, and that the exposure to amicacin and vancomycin on the recommended dose by Neofax®, 2003/2004 did not alter the amplitude of the emissions in the newborns without risk indicators concomitant with neonatal infection.
62

"Emissões otoacústicas produto de distorção em recém-nascidos medicados com ototóxicos" / Distortion product otoacoustic emission in newborn exposed to ototoxic

Marisa Ruggieri Marone 22 June 2006 (has links)
INTRODUÇÃO: Os aminoglicosídeos são freqüentemente usados no berçário e podem ser tóxicos para as células ciliadas cócleo-vestibulares, especialmente para as células ciliadas externas da base da cóclea. As emissões ototacústicas produto de distorção permitem avaliar porções específicas da cóclea, antes mesmo que a sensação auditiva seja alterada, sendo ideais para análise precoce da integridade dessa estrutura auditiva, além de ser indicada para recém-nascidos por serem objetivas. O objetivo deste estudo prospectivo longitudinal é pesquisar a amplitude das emissões otoacústicas produto de distorção, causadas pelo uso de drogas ototóxicas, entre o término da administração e de 15 a 40 dias após seu uso. MÉTODOS: A população foi de recém-nascidos a termo e pré-termo provenientes de berçário e maternidade de um hospital público em Santo André, no período de julho de 2003 a setembro de 2004. A primeira avaliação ocorreu no dia da alta hospitalar. Foram avaliados três grupos: grupo controle com 33 recém-nascidos saudáveis e de termo; grupo de estudo a termo exposto a amicacina e /ou vancomicina com 19 recém-nascidos com mais de 37 semanas e grupo de estudo pré-termo exposto aos mesmos ototóxicos, com 15 recém-nascidos de 32 a 37 semanas. Os recém-nascidos não apresentavam indicadores de risco para deficiência auditiva preconizados pelo JCIH,2000 concomitante à infecção neonatal. Todos os recém-nascidos foram avaliados com idade gestacional corrigida maior que 37 semanas. As amplitudes das emissões otoacústicas dos recém-nascidos em fase de alta hospitalar foram comparadas às obtidas de 15 a 40 dias após a alta. RESULTADOS: As amplitudes das emissões otoacústicas dos recém-nascidos do grupo de estudo pré-termo foram menores que as amplitudes do grupo controle e do grupo de estudo a termo nos dois momentos de teste. As amplitudes das emissões dos recém-nascidos dos três grupos aumentaram no segundo momento de teste. As amplitudes das emissões dos recém-nascidos foram maiores na freqüência de 6.000 Hz e na orelha direita para a freqüência f2 3.000 Hz. As amplitude das emissões do grupo controle no segundo momento de teste foram semelhantes as do grupo de estudo à termo no primeiro momento da pesquisa. CONCLUSÔES: Houve aumento da amplitude das emissões otoacústicas produto de distorção desde a fase de alta até 15 a 40 dias após. A exposição a amicacina e vancomicina nas doses preconizadas pelo Neofax®, 2003/2004 não alterou as amplitudes das emissões nos recém-nascidos sem indicadores de risco concomitante à infecção neonatal. / The amynoglicosides are frequently used in nurseries and may be toxic for the cochleo-vestibular hair cells, specially for the outer cells of the cochlear base. The distortion product otoacoustic emissions allow to evaluate specific portions of the cochlea even before the hearing sensation is altered, and are ideal for the early analysis of this auditory structure integrity, besides being indicated for newborns once they are objective. The aim of this prospective longitudinal study is to research the amplitude of distortion product otoacoustic emissions caused by the ototoxic drugs use, between the end of the administration and from 15 to 40 days after its use. The population studied was composed by term and preterm newborns from a nursery and maternity of a Santo André city hospital, in the period from July 2003 to September 2004. The first evaluation occurred on the hospital discharge day. Three groups were evaluated: control group with 33 term and healthy newborns; term study group with 19 term newborns with more than 37 weeks exposed to amicacin and/or vancomycin; and preterm study group with 15 preterm newborns from 32 to 37 weeks exposed to the same ototoxic. The newborns did not present risk factors for hearing loss according to the JCIH, 2000 concomitant to the neonatal infection. All newborns were evaluated at a corrected gestational age greater than 37 weeks. The otoacoustic emissions amplitudes obtained at the hospital discharge were compared to the ones obtained from 15 to 40 days after the discharge. The results showed that the otoacoustic emissions amplitudes of the preterm study group were smaller than the amplitudes of the control group and the term study group in both moments of the test. The amplitude of the newborns’ otoacoustic emissions increased in the second moment of the test. The amplitudes were higher in the frequency of 6.000Hz and, in the right ear in the frequency f2 3.000 Hz. The otoacoustic emissions amplitudes of the control group in the second moment of the test were similar to the term study group in the first moment of the research. It was concluded that there is an increase of the distortion product otoacoustic emissions amplitude from the discharge moment until 15 to 40 days after, suggesting a maturation of the cochlear structures in the post-natal period, and that the exposure to amicacin and vancomycin on the recommended dose by Neofax®, 2003/2004 did not alter the amplitude of the emissions in the newborns without risk indicators concomitant with neonatal infection.
63

Identification of an Orally Bioavailable, Brain-Penetrant Compound with Selectivity for the Cannabinoid Type 2 Receptor

Ospanov, Meirambek, Sulochana, Suresh P., Paris, Jason J., Rimoldi, John M., Ashpole, Nicole, Walker, Larry, Ross, Samir A., Shilabin, Abbas G., Ibrahim, Mohamed A. 14 January 2022 (has links)
Modulation of the endocannabinoid system (ECS) is of great interest for its therapeutic relevance in several pathophysiological processes. The CB2 subtype is largely localized to immune effectors, including microglia within the central nervous system, where it promotes anti-inflammation. Recently, a rational drug design toward precise modulation of the CB2 active site revealed the novelty of Pyrrolo[2,1-c][1,4]benzodiazepines tricyclic chemotype with a high conformational similarity in comparison to the existing leads. These compounds are structurally unique, confirming their chemotype novelty. In our continuing search for new chemotypes as selective CB2 regulatory molecules, following SAR approaches, a total of 17 selected (S,E)-11-[2-(arylmethylene)hydrazono]-PBD analogs were synthesized and tested for their ability to bind to the CB1 and CB2 receptor orthosteric sites. A competitive [H]CP-55,940 binding screen revealed five compounds that exhibited >60% displacement at 10 μM concentration. Further concentration-response analysis revealed two compounds, and , as potent and selective CB2 ligands with sub-micromolar activities ( = 146 nM and 137 nM, respectively). In order to support the potential efficacy and safety of the analogs, the oral and intravenous pharmacokinetic properties of compound were sought. Compound was orally bioavailable, reaching maximum brain concentrations of 602 ± 162 ng/g (p.o.) with an elimination half-life of 22.9 ± 3.73 h. Whether administered via the oral or intravenous route, the elimination half-lives ranged between 9.3 and 16.7 h in the liver and kidneys. These compounds represent novel chemotypes, which can be further optimized for improved affinity and selectivity toward the CB2 receptor.
64

Exploratory Analysis of Impact of Gabapentin on Incidence of Postoperative Nausea and Vomiting in Patients Undergoing Knee and Hip Arthroplasty With Neuraxial Anesthesia

Teeples, Allison J., Flynn, David, Denslow, Sheri, Hooper, Vallire 01 October 2020 (has links)
The incidence of postoperative nausea and vomiting (PONV) is unknown in neuraxial anesthesia for orthopedic surgery. The effect on PONV of adding gabapentin to an evidence-based antiemetic regimen as part of an opioid-sparing analgesic protocol is also unknown in this population. A retrospective analysis of all adults undergoing hip and knee arthroplasty and receiving neuraxial anesthesia in 2017 was conducted. The overall incidence of PONV was assessed. Additionally, PONV incidence was assessed for all combinations of gabapentin, dexamethasone, and/or ondansetron (in addition to propofol infusion) and compared with propofol alone. The PONV risk ratios were estimated, adjusting for age and PONV risk score. The overall incidence of PONV was 14.0%. The addition of gabapentin to propofol was associated with reduced PONV (multivariable risk ratio [mRR], 0.6; 95% CI, 0.4-1.0) vs propofol alone. Dexamethasone with propofol was associated with reduced PONV (mRR 0.6; 95% CI, 0.4-1.1) vs propofol alone, although not statistically significant. The addition of both gabapentin and dexamethasone to propofol was associated with stronger reduction in PONV (mRR 0.3; 95% CI, 0.1-0.7) vs propofol alone. Adding ondansetron to propofol showed little benefit. Gabapentin and dexamethasone are effective in reducing PONV in patients undergoing knee and hip arthroplasty with neuraxial anesthesia.
65

Pharmacokinetics of Moricizine in Young Patients

Rice, P J., LeClair, I O., Stone, W L., Mehta, A. V 01 October 1995 (has links)
Moricizine is a novel phenothiazine antiarrhythmic agent that depresses the activity of ectopic foci, has a low incidence of adverse effects relative to other agents, and is useful in treating pediatric atrial ectopic tachycardia. A study was conducted to determine the pharmacokinetics of moricizine in children after oral administration. Moricizine was isolated from frozen serum obtained from four male patients (ages 7, 8, 9, and 18 years) receiving the drug for supraventricular tachycardia and analyzed by high-performance liquid chromatography with ultraviolet detection according to an established protocol. Peak serum levels were between 400 and 2000 ng/mL. Elimination of moricizine did not follow simple single-compartment pharmacokinetics. In three patients we observed an increase or slower decline in blood level occurring after 4 hours. Because of the paroxysmal nature of the tachycardias, decreases in patient heart rate could not be correlated with moricizine blood level. These results suggest that the pediatric pharmacokinetics of moricizine excretion are complex and may differ from those seen in adults.
66

"Prática de medicina baseada em evidências em um centro de tratamento intensivo pediátrico" / The practice of evidence-based medicine in a pediatric intensive care unit

Carlos Augusto Cardim de Oliveira 17 December 2003 (has links)
Objetivos: Estimar a concordância entre as práticas e as evidências disponíveis em uma unidade de terapia intensiva pediátrica. Métodos: Estudo retrospectivo de todos os pacientes internados durante 2001. As práticas foram classificadas em adequadas ou não-adequadas de acordo com recomendações. Esperava-se para as práticas recomendadas 90% de concordância, para as contra-indicadas, discordância de até 10% e para aquelas onde havia incertezas, 50%. Resultados: Foram selecionadas 114 publicações e avaliadas 253/275 internações (92%). O uso foi considerado apropriado para albumina em 47,6% (IC 95% 39% – 55%); dopamina <3mg/kg/min 87,9% (83% – 92%); sedação e analgesia 88,6% (87% – 90%); transfusões de concentrado de hemácias 95,2% (92% – 97%); profiliaxia de úlcera de estresse 89,7% (88% – 91%). / Objectives: Estimate the concordance between the practices and the evidence available in a pediatric intensive care unit. Methods: Retrospective study of all admitted patients during 2001. The practices were classified as adequate or non-adequate according to recommendations. It was expected 90% concordance for the recommended practices, while for non-adequate practices, discordance until 10% and for those where there was doubt, 50%. Results: 114 publications were selected and 253/275 admissions (92%) were evaluated. Use was considered appropriate for albumin in 47.6% (IC 95% 39% – 55%); dopamine <3mg/kg/min 87.9% (83% – 92%); sedation and analgesia 88.6% (87% – 90%); red blood cell transfusions 95.2% (92% – 97%); stress ulcer prophylaxis 89.7% (88% – 91%).
67

"Prática de medicina baseada em evidências em um centro de tratamento intensivo pediátrico" / The practice of evidence-based medicine in a pediatric intensive care unit

Oliveira, Carlos Augusto Cardim de 17 December 2003 (has links)
Objetivos: Estimar a concordância entre as práticas e as evidências disponíveis em uma unidade de terapia intensiva pediátrica. Métodos: Estudo retrospectivo de todos os pacientes internados durante 2001. As práticas foram classificadas em adequadas ou não-adequadas de acordo com recomendações. Esperava-se para as práticas recomendadas 90% de concordância, para as contra-indicadas, discordância de até 10% e para aquelas onde havia incertezas, 50%. Resultados: Foram selecionadas 114 publicações e avaliadas 253/275 internações (92%). O uso foi considerado apropriado para albumina em 47,6% (IC 95% 39% – 55%); dopamina <3mg/kg/min 87,9% (83% – 92%); sedação e analgesia 88,6% (87% – 90%); transfusões de concentrado de hemácias 95,2% (92% – 97%); profiliaxia de úlcera de estresse 89,7% (88% – 91%). / Objectives: Estimate the concordance between the practices and the evidence available in a pediatric intensive care unit. Methods: Retrospective study of all admitted patients during 2001. The practices were classified as adequate or non-adequate according to recommendations. It was expected 90% concordance for the recommended practices, while for non-adequate practices, discordance until 10% and for those where there was doubt, 50%. Results: 114 publications were selected and 253/275 admissions (92%) were evaluated. Use was considered appropriate for albumin in 47.6% (IC 95% 39% – 55%); dopamine <3mg/kg/min 87.9% (83% – 92%); sedation and analgesia 88.6% (87% – 90%); red blood cell transfusions 95.2% (92% – 97%); stress ulcer prophylaxis 89.7% (88% – 91%).
68

Ultradiluição homeopática de triiodotironina altera a apoptose celular da cauda de girinos de Rana catesbeiana: in vitro / Ultra high dilution of triiodothyronine modifies the cellular apoptosis of Rana catesbeiana tadpole tail: in vitro

Guedes, José Roberto Pereira 11 March 2010 (has links)
Ultradiluição (UHD) é o efeito de uma solução, diluída acima do número de Avogrado, que na dependência da sua dinamização (diluição com sucussão) induz um efeito celular supressivo ou estimulante, com conseqüente obtenção de uma curva dose-efeito oscilatória. Por outro lado, a 3,3,5 Triiodo-L-Tironina (T3) é o hormônio mais importante na indução e manutenção das mudanças metamórficas dos girinos, nelas incluídas a absorção da cauda. O presente estudo, cego e randomizado, tem como objetivo comprovar que o T3 5.10-24M (10ª cH) altera a apoptose induzida pelo T3 100 nM na cauda de girinos de Rana catesbeiana, in vitro. Foram distribuídos 60 explantes em três grupos: Grupo A: sem o estímulo do T3 em dose farmacológica e em UHD; Grupo B (teste): sob a ação de T3 100 nM e T3 10ª cH (5.10-24 M); Grupo C (controle): sob a ação do T3 100 nM e etanol 70% sem sucussão. A análise estatística da área dos explantes, no primeiro e ultimo dia do experimento, e do índice apoptótico foi realizado através do teste t Student e foi considerado estatisticamente significante quando p<0,05. Embora sem diferenças significativas na área dos explantes do grupo teste e no grupo controle, um maior e significante índice apoptótico foi identificado nos explantes do grupo teste. Este resultado confirma que o T3 na 10ª cH altera a ação do T3 em dose farmacológica. Futuros experimentos serão realizados, com diferentes dinamizações, com o objetivo da parametrização da curva dose-efeito / Ultra High Dilution (UHD) is the effect of a solution, beyond the Avogadro limits, that in the dependence of the applied dinamization (dilution with succussion) elicits a suppressive or a stimulant effect on a living cell, with a consequent generation of an oscillatory dose-effect curve. The entire process of anuran amphibian metamorphosis is under thyroid hormones control, included the complete resorption of the tadpole tail. A random and blind study was performed, with the intent to prove that T3 5.10-24 M (10ª cH) modifies the apoptosis induction of T3 100 nM in Rana catesbeiana tadpoles tail tips, in vitro. 60 Explants were distributed in three ways: Group A: without T3 action, at pharmacological and UHD dose; Group B (test): under the action of T3 100 nM and treated with T3 10ª cH (UHD); Group C (control): under the action of T3 100 nM and treated with ethanol 70% unsuccussed. In order to identify significant differences in the area of the remainder explants, at the first and final day of the experiment, and in the apoptotic index we used a student t-test. Although we didnt find statistical difference in macroscopic tadpoles tail tips area from test and control groups, a high and significant (p<0,05) index of apoptosis in histology was found in explants of test group. This data confirms that T3 10 cH modifies the effect of T3 at pharmacological dose. More studies will be necessary, using different dinamizations, to the parameterization of the dose-effect curve proceeding from these experiments
69

Avaliação dos efeitos pulmonares e sistêmicos agudos em resposta à injeção intrapleural de talco de diferentes tamanhos de partículas / Pulmonary and systemic response following intrapleural instillation of talc with different particle size

Figueiredo, Viviane Rossi 16 January 2007 (has links)
Pacientes com comprometimento pleural por neoplasias malignas freqüentemente apresentam derrame pleural recidivante. Nestes casos, a sínfise das membranas pleurais (pleurodese) com a finalidade de evitar o acúmulo de líquido no espaço pleural deve ser considerada. O talco é o agente mais utilizado indicado para essa finalidade. Entretanto, seu uso terapêutico continua controverso devido aos efeitos deletérios que podem advir de sua utilização. O mais grave entre todos é a insuficiência respiratória aguda, que pode evoluir para a síndrome do desconforto respiratório agudo (SDRA). Essa complicação pode estar relacionada com a composição, com o tamanho das partículas de talco e com a resposta inflamatória desencadeada pelas mesmas. O objetivo deste estudo foi avaliar os efeitos pulmonares e sistêmicos em resposta à injeção intrapleural (IIP) de talco de partículas pequenas (TP) e de partículas de tamanhos diversos (TM). Cem coelhos foram submetidos à IIP com talco. Metade dos animais foi injetada com TP (diâmetro médio= 6,41 mm) e outra metade com TM (diâmetro médio= 21,15 mm), que é o talco usado na prática clínica. Quinze coelhos compuseram o grupo controle. Foram avaliados a celularidade, os níveis de desidrogenase lática (DHL), proteína C reativa (PCR), interleucina-8 (IL-8) e fator de crescimento endotelial vascular (VEGF) no sangue e no lavado broncoalveolar (LBA) às 6, 24, 48, 72 e 96 horas após a IIP. Realizou-se também a quantificação de partículas de talco e a análise histológica dos pulmões. Utilizamos o teste t e Anova na análise estatística, considerando p< 0,05 como significância estatística. A maioria dos parâmetros avaliados apresentou níveis mais elevados no sangue e no LBA dos animais injetados com TP ou TM quando comparados ao grupo controle, sugerindo uma resposta sistêmica e pulmonar à IIP de talco. Com relação aos grupos de talco, os níveis de PCR e de IL-8 apresentaram-se mais elevados no sangue e no LBA dos animais injetados com TP. Partículas de talco foram observadas em todas as lâminas examinadas, sem diferenças significativas entre os grupos. Os pulmões dos animais injetados com TP apresentaram infiltrado linfomononuclear mais exuberante que no grupo TM. A resposta inflamatória pulmonar antecedeu (24 h) a resposta sistêmica (48 h), sugerindo que o pulmão é o principal órgão da resposta sistêmica aguda. Estes achados estudo nos permitem concluir que o talco calibrado com partículas maiores deva ser utilizado na prática clínica, objetivando uma pleurodese mais segura. / Talc has been the pleurodesis agent of choice for the local treatment of recurrent pleural diseases. However, serious concerns exist about its safety. The acute respiratory failure is considered its most serious complication. The physiopathologic mechanisms involved are still unclear. It has been attributed to the systemic dissemination of small talc particles, to the composition of talc and to the inflammatory response. The purpose of this study was to evaluate the systemic and pulmonary response following intrapleural instillation of small particles talc (ST) and mixed particles talc (MT). One hundred rabbits received intrapleural instillation of talc as follows: fifty rabbits were instilled with ST (mean diameter=6,41 microns), and 50 rabbits with MT (mean diameter= 21,15 microns). As control (without talc instillation) were used 15 animals. We studied the pulmonary and systemic inflammatory response (total cell count and differential, levels of lactate dehydrogenase (LD), C-reactive protein (PCR), interleukin-8 (IL-8) and human vascular endothelial growth factor (VEGF) in serum and bronchoalveolar lavage (BAL). Histologic analysis of both lungs and quantitation of talc particles were done at 6, 24, 48, 72 and 96h. ST group showed higher pulmonary and systemic inflammatory response than did the MT group. PCR and IL-8 concentrations were higher in serum and BAL of ST group than the MT group. Many talc particles were observed in the pulmonary tissue of both talc groups, but without statistical significance. We also observed a predominance of cellular infiltrates (lymphomononuclear cells) in the lungs of ST group. The pulmonary inflammatory response (increased IL-8 in BAL) was earlier (24h) than the systemic inflammatory response (48 h). These observations suggest that the main organ in the systemic inflammatory acute response is lung. So, we recommend the clinical use of mixed talc without small particles to induce safety pleurodesis.
70

"Tratamento do cisto renal simples sintomático por aspiração percutânea e injeção permanente de álcool absoluto em sessão única" / Treatment of symptomatic simple renal cyst with percutaneous aspiration and single-session permanent 99.5% ethanol injection

Falci Junior, Renato 04 March 2005 (has links)
Foram estudados prospectivamente 33 pacientes cujos cistos tinham volume médio de 298,4 + 346,9 (30 - 1700) ml. A punção foi realizada sob anestesia local com agulha 18 gauge, de 20 cm. Após seu esvaziamento, injetou-se etanol absoluto no volume equivalente a um terço do volume aspirado, até o máximo de 100 ml. Os volume médios observados após um, três e seis meses foram 47,9 + 59,4 (0 - 286) ml, 25,2 + 42,8 (0 - 208) ml e 12,7 + 30 (0 - 120) ml, respectivamente. Após esse período, 30 (91%) apresentaram remissão total dos sintomas, 2 (6%) mantiveram os sintomas, sendo um com cisto residual e outro sem cisto e um (3%) apresentou melhora parcial dos sintomas / A prospective series of 33 patients with symptomatic simple renal cysts varying from 30 to 1700 ml, were considered eligible for the study. The cysts were punctured under local anesthesia with an 18 gauge, 20 centimeters needle. A volume of ethanol equivalent to one third of the aspirated volume, up to a maximum of 100 ml, was injected into the cyst and left there. After one, three and six months, the average volume of the cyst was 47.9 + 59.4 (0 - 286)ml, 25.2 + 42.8 (0 - 208)ml and 12.7 + 30 (0 - 120)ml, respectively. After this period, 30 patients (91%) showed total remission of the symptoms, two patients (6%) maintained them and one patient (3%) had partial remission of the symptoms

Page generated in 0.1616 seconds